Investing.com - CureVac NV reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
CureVac NV announced earnings per share of €-0.25 on revenue of €11.2M. Analysts polled by Investing.com EPS of €-0.27 on revenue of €20.33M.
CureVac NV 's are down 76% and is trading at €8.00 , still down 83.69% from its 52 week high of €50.09 set on Tuesday, November 30, 2021.
CureVac NV follows other major Healthcare sector earnings this month
CureVac NV's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of €1.98 on revenue of €6.94B, EPS of €1.91 on revenue of €6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of €1.78 on revenue of €22.6B, for EPS of €1.44 on revenue of €21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar